Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 6-K, Date: 2020-04-14
Original SEC Filing: Click here

---

Webplus: SVA/20200414/6-K/2_EX-99.1/000.htm SEC Original: tm2015841d1_ex99-1.htm
Sinovac Announces Approval of Human Clinical Trial for a Vaccine Candidate Against COVID-19 BEIJING–(BUSINESS WIRE)– April 14, 2020– Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Company has obtained approval to conduct a human clinical trial on an inactivated SARS-CoV-2 (commonly referred to as COVID-19) vaccine candidate. The

---

---

Webplus: SVA/20200414/6-K/1/000.htm SEC Original: tm2015841d1_6k.htm

---

Company Info:

Ticker: SVA, Company: SINOVAC BIOTECH LTD, Type: 6-K, Date: 2020-04-14CIK: 0001084201, Location: F4, SIC: 2834, SIC Desc: PHARMACEUTICAL PREPARATIONS
Business Phone & Address:
NO. 15 ZHI TONG ROAD,, ZHONGGUANCUN TECH PARK, CHANGPING DISTR.
BEIJING 102200